Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease

IF 12.9 1区医学 Q1 HEMATOLOGY

Blood Cancer Journal Pub Date : 2024-08-23 DOI:10.1038/s41408-024-01127-2

Jialing Lu, Xiebing Bao, Jihao Zhou, Xiaoli Li, Zhewei He, Yujie Ji, Shengli Xue, Suning Chen, Depei Wu, Qi Hu, Peng Ke, Xiao Ma

引用次数: 0

Abstract Image

查看原文本刊更多论文

blinatumomab 作为 B 细胞急性淋巴细胞白血病首次完全缓解且未检测到最小残留病的移植桥接疗法的安全性和有效性

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Journal ONCOLOGY-

CiteScore

16.70

自引率

2.30%

发文量

153

审稿时长

>12 weeks

期刊介绍： Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as: Preclinical studies of new compounds, especially those that provide mechanistic insights Clinical trials and observations Reviews related to new drugs and current management of hematologic malignancies Novel observations related to new mutations, molecular pathways, and tumor genomics Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.